Ex vivo and preclinical assessment of an endothelial progenitor cell capturing bioengineered stent.
Although drug-eluting stents (DES) have significantly reduced the rates of restenosis as compared to bare metal stents, late stent thrombosis remains a major drawback, especially for "off-label" use. Delayed arterial healing, characterized by persistent fibrin deposition and poor endothelialization, has been shown to correlate with late DES thrombosis. To overcome these limitations, a "pro-healing" approach has been developed to capture circulating endothelial progenitor cells (EPC) to enhance endothelialization of the stent surface. EPC have the ability to migrate to sites of vascular injury and aid the regeneration of damaged and dysfunctional endothelium. Clinically, the safety of EPC-capture stent has been proven in numerous clinical trials with low incidence of late stent thrombosis. The focus of this review is to demonstrate the efficacy of the Genous stent in preclinical studies, specifically to show the effectiveness of the anti-CD34+ coating in promoting endothelialization and reducing thrombogenicity.
CVPath Institute, Inc., Gaithersburg, MD, USA.
S K
SK
Yazdani
F D
FD
Kolodgie
R
R
Virmani
D000818:Animals; D002465:Cell Movement; D042783:Endothelial Cells / Q000502:physiology*; D006801:Humans; D008954:Models, Biological; D011474:Prosthesis Design; D015607:Stents; D023822:Tissue Engineering